SCM
BCRX icon

Sterling Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sterling Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18K Sell
818
-1,280
-61% -$11.6K ﹤0.01% 2332
2026
Q1 		$20K Buy
2,098
+707
+51% +$5.49K ﹤0.01% 2029
2025
Q4 		$10.8K Buy
1,391
+883
+174% +$6.38K ﹤0.01% 2564
2025
Q3 		$3.86K Buy
508
+9
+2% +$75 ﹤0.01% 2841
2025
Q2 		$4.47K Buy
499
+276
+124% +$2.57K ﹤0.01% 2571
2025
Q1 		$1.67K Buy
223
+13
+6% +$105 ﹤0.01% 2654
2024
Q4 		$1.58K Hold
210
– – ﹤0.01% 2842
2024
Q3 		$1.6K Buy
+210
New +$1.6K ﹤0.01% 2302

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Sterling Capital Management's BCRX Position: Q2 2026 in Review

Sterling Capital Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 61% in Q2 2026, selling an estimated $11.6K and leaving 818 shares worth $8.18K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Sterling Capital Management first reported a position in BCRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $20K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Sterling Capital Management held 818 shares of BioCryst Pharmaceuticals worth $8.18K as of Q2 2026.
  • Sterling Capital Management sold 1,280 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $11.6K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2332 holding.
  • Sterling Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's BioCryst Pharmaceuticals position peaked at $20K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.